GTC
CBIO

Ghost Tree Capital’s Crescent Biopharma CBIO Stock Holding History

Ghost Tree Capital’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4,000
Closed -$5.76M – 50
2018
Q3 		$5.76M Hold
4,000
– – 1.22% 29
2018
Q2 		$6.45M Buy
4,000
+1,500
+60% +$2.58M 1.9% 22
2018
Q1 		$4.06M Buy
+2,500
New +$5.2M 0.82% 38

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Ghost Tree Capital's CBIO Position: Q4 2018 in Review

Ghost Tree Capital sold out of Crescent Biopharma (CBIO) in Q4 2018, closing a stake of 4,000 shares — an estimated $5.76M sold.

Ghost Tree Capital first reported a position in CBIO in Q1 2018 and held it in 3 quarters. The position peaked at $6.45M in Q2 2018. 81 funds tracked by Wall St. Rank hold CBIO as of Q4 2018.

  • Ghost Tree Capital reported no remaining Crescent Biopharma position as of Q4 2018 after selling out during the quarter.
  • Ghost Tree Capital sold 4,000 Crescent Biopharma shares in Q4 2018, an estimated $5.76M.
  • Ghost Tree Capital first reported a position in Crescent Biopharma in Q1 2018 and held it in 3 quarters.
  • Ghost Tree Capital's Crescent Biopharma position peaked at $6.45M in Q2 2018.
  • 81 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2018.

Based on Ghost Tree Capital's 13F filing for Q4 2018, filed 14 Feb 2019.